Steven Ades

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

Crizotinib in Patients With MET-Amplified NSCLC

D. Ross Camidge, Gregory A. Otterson, Jeffrey W. Clark et al. · Journal of Thoracic Oncology · 2021 · 163 citations · Full text

Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial

Lorenzo Ferri, Steven Ades, Thierry Alcindor et al. · Annals of Oncology · 2011 · 102 citations · Full text

Advanced Esophageal, Esophageal Cancer, Gastrointestinal Oncology +8

Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer

Steven Ades, Shailesh Kumar, Murad Alam et al. · Journal of Thrombosis and Haemostasis · 2015 · 85 citations

Venous Disease, Venous Thrombosis, Oncogenic Agent +8

Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.

D. Ross Camidge, Gregory A. Otterson, Jeffrey W. Clark et al. · Journal of Clinical Oncology · 2018 · 79 citations

Preclinical Therapeutics, Cardiovascular Pharmacology, Pathology +24